Study title: Schellong-G, Braemswig-J-H, Hoernig-Franz-I, Schwarze-E-W, Poetter-R, Wannenmacher-M. Children's Hospital, University of Muenster, Germany. Hodgkin's disease in children: combined modality treatment for stages IA, IB, and IIA. Results in 356 patients of the German/Austrian Pediatric Study Group. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, {Ann-Oncol}, 1994, vol. 5 Suppl 2, p. 113-5, ISSN: 0923-7534.Schellong-G, Braemswig-J-H, Hoernig-Franz-I, Schwarze-E-W, Poetter-R, Wannenmacher-M. Children's Hospital, University of Muenster, Germany. Hodgkin's disease in children: combined modality treatment for stages IA, IB, and IIA. Results in 356 patients of the German/Austrian Pediatric Study Group. Annals of oncology : official j...
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Neoplasms [C04] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: PROCARBAZINE | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |